Analyst firms · Needham · TRVI
Needham TRVI price target and rating history
Trevi Therapeutics Inc. (TRVI) · Health Care
Needham rates Trevi Therapeutics Inc. (TRVI) Buy with a $25 price target, as of its latest action on Mar 10, 2025. It has published 3 rating actions on TRVI since August 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $25
- Median target, all firms
- Too few
- Actions on TRVI
- 3
Needham price target on TRVI
Every Needham rating on TRVI
- Mar 10, 2025
- Nov 11, 2021
- Aug 13, 2021
How other firms rate TRVI
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Outperform | $36 | Jul 21, 2026 |
| Leerink Partners | Outperform | $13 | Nov 13, 2025 |
Questions about Needham and TRVI
- What is Needham's price target for TRVI?
- Needham's latest stated price target for Trevi Therapeutics Inc. (TRVI) is $25, from its action on Mar 10, 2025.
- What is Needham's rating on TRVI?
- Needham rates TRVI Buy, a bullish rating, as of Mar 10, 2025.
- When did Needham last change its view on TRVI?
- On Mar 10, 2025, Needham raises its price target to $25 from $8, keeps Buy.
More TRVI rating histories
All Needham ratingsTRVI news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.